Winship Cancer Institute of Emory University | Strategic Alliance Partners

Suresh S. Ramalingam, MD, sheds light on the recent data with emerging agents in small cell lung cancer.

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses immunotherapy in Merkel cell carcinoma.

The National Cancer Institute has named Winship Cancer Institute at Emory University a Comprehensive Cancer Center.

Ragini Kudchadkar, MD, assistant professor, Department of Hematology and Medical Oncology, associate director, Hematology and Medical Oncology Fellowship Program-Clinical/Service, Emory University School of Medicine, discusses the FDA approval of avelumab for the treatment of patients with Merkel cell carcinoma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.

Osimertinib, an EGFR tyrosine kinase inhibitor (TKI), is quickly emerging as a therapeutic option for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who develop the acquired resistance mutation T790M.

Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses the potential of the combination regimen of pomalidomide (Pomalyst) and daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Although advances have been made in imaging techniques for patients with glioblastoma multiforme, new tools are needed to supplement standard imaging sequences.

Suresh Ramalingam, MD, professor, Emory School of Medicine, and chief, Medical Oncology, Department of Hematology and Medical Oncology, Emory University, discusses combinations with immunotherapy agents and chemotherapy being investigated as potential treatments for patients with non–small cell lung cancer.

Sagar Lonial, MD, chief medical officer at Winship Cancer Institute of Emory University, discusses novel mechanisms of agents used for the treatment of patients with multiple myeloma.

Suresh Ramalingam, MD, discusses the evolving role of checkpoint inhibitors in lung cancer and what challenges still remain.

Between immunotherapies and targeted therapies-both of which certainly offer bold new opportunities for disease control over cytotoxic therapies-which treatment modality do oncologists think has had the greatest overall impact on NSCLC treatment?

Five years from now multiple myeloma will have a therapeutic backbone consisting entirely of combinations of novel agents.

New drug candidate necitumumab, which is being reviewed by the FDA as a treatment for patients with locally advanced or metastatic squamous non-small cell lung cancer, received a low cost-effectiveness evaluation in a study published in JAMA Oncology.

Walter J. Curran, Jr., MD, Executive Director, Winship Cancer Institute of Emory University, Associate Vice President, Woodruff Health Sciences Center, discusses new developments in the delivery of radiation for patients with lung cancer.

The landscape of therapeutic options for patients with myeloma at all phases of treatment has rapidly changed with the development of new drugs and targets.

Sagar Lonial, MD, discusses the future of monoclonal antibodies in multiple myeloma.

Daniel J. Brat, MD, PhD, vice chair, Translational Programs, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, director, Cancer Tissue and Pathology Shared Resource, Winship Cancer Institute, discusses genomic characterization of diffuse lower grade gliomas.

The role of mTOR inhibition in breast cancer is evolving, and ongoing studies are evaluating biomarkers that will identify the patients who will benefit.

Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.

Nivolumab improved survival versus docetaxel in patients with pretreated squamous cell non–small cell lung cancer in the phase III CheckMate-017 trial.

Suresh S. Ramalingam, MD, discusses results from a phase II trial exploring the potential of veliparib as a treatment for patients with squamous cell NSCLC.

Although the incidence and mortality of prostate cancer remain formidable problems in the United States, clinicians have many new agents with proven overall survival (OS) benefits to recommend for patients with metastatic disease.

Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.

Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses treating younger patients with breast cancer.

Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, explains why more women with breast cancer are electing to get contralateral prophylactic mastectomies (CPMs)